Le Lézard1h
U.S. FDA Grants Full Approval of Deciphera's ROMVIMZAtm (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; "Ono") announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZAtm (vimseltinib), a kinase ...
Scientists propose CDK2 enzyme as new target for cancer therapy
An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...
Medindia1d
MYCN and MDM2: A Transformative Strategy in Cancer Therapy
Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality.
Hosted on MSN1d
Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 Inhibitor
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced significant findings about ATI-2138, a novel investigational drug ...